Inclusion Criteria:  Age > 18 and ≤ 80 years old Heterogeneous emphysema with upper lobe predominance in at least one lung segment to be treated (defined as a Heterogeneity Index (HI) ≥ 1.3 per CT) Post-bronchodilator FEV1 ≥ 15% and ≤ 45% of predicted value Total lung capacity (TLC) ≥ 100% predicted Post-bronchodilator Residual volume (RV) ≥ 200% predicted 6-minute walk distance (6MWD) > 100m and ≤ 450m (Partial Pressure of Oxygen) PaCO2 ≤ 45 mm Hg; PaO2 > 45 mm Hg on room air  Non-smoking for 4 months prior to study enrollment as confirmed by:  negative urine analysis or serum cotinine level of ≤ 10 ng/mL, or negative CO Hb test OR If using smoking cessation product(s) containing nicotine at screening, serum cotinine level ≤ 13.7 ng/ml (or arterial carboxyhemoglobin ≤ 2.5%)  Optimized medical management (consistent with GOLD guidelines)  Pharmacological:  1.Long acting bronchodilator (LABA),Long-acting muscarinic antagonists (LAMA), LAMA + LABA, or LABA + ICS > 1 year  b. Evidence of completed Pulmonary Rehabilitation  ≥ 6 weeks out-patient or ≥ 3 weeks in-patient within 12 months of enrollment; or, Patient has or continues to participate in at home rehabilitation program (i.e. a walking program) within 6 weeks of enrollment under the supervision of a health care professional  10. Mentally and physically able to provide written informed consent to participate in the study  Exclusion Criteria:  DLCO < 20% predicted Uncontrolled pulmonary hypertension (systolic pulmonary arterial pressure >45 mm Hg) or evidence or history of cor pulmonale as determined by recent echocardiogram Clinically significant bronchiectasis Clinically significant (greater than 4 tablespoons per day) sputum production. Two (2) or more COPD exacerbations or pneumonia episodes requiring hospitalization in the last year Evidence of active infection in the lungs at the time of procedure. Daily use of systemic steroids, > 10 mg prednisolone (or equivalent) daily. Lung pathology of nodule not proven stable or benign Clinically significant pulmonary fibrosis Prior lung transplant, lung volume reduction surgery (LVRS), bullectomy, or lobectomy Prior lung volume reduction via endobronchial valves(s), coil(s), and/or polymer. Note: Patients whose endobronchial valves have been removed can be treated if: all valves removed ≥ 3 months prior to InterVapor and baseline bronchoscopy reveals no airway obstruction or obvious tissue granulation Large bulla (defined as > 1/3 volume of the lobe) Highly diseased upper and lower lobes in contralateral lung (%-950 >50%) Paraseptal emphysema in any segment targeted for treatment Myocardial Infarction or congestive heart failure within 6 months of screening. Diagnosis of heart failure with Left Ventricular Ejection Fraction (LVEF) < 45% as determined by recent echocardiogram (completed within 3 months prior to screening). Unable to safely discontinue anti-coagulants or platelet inhibitors for 6 weeks post procedure. Body mass index (BMI) > 32 kg/m2 Patient taking immunosuppressive drugs for the treatment of cancer, rheumatic arthritis, autoimmune disease, or prevention of tissue or organ rejection. Subject is pregnant or lactating, or plan to become pregnant within the study timeframe Any disease or condition that is likely to limit survival to less than one year Concomitant illnesses or medications that may pose a significant increased risk for complications following treatment with InterVapor® Currently enrolled in another clinical trial studying an experimental treatment. Any condition that would interfere with completion of the study including study assessments and study procedure including bronchoscopy.